Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)

Trial Profile

Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Acronyms BELIEVE 1
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 10 Apr 2018 According to a Zynerba Pharmaceuticals media release, this study has been initiated.
    • 10 Apr 2018 Planned number of patients changed from 48 to 50, according to a Zynerba Pharmaceuticals media release.
    • 10 Apr 2018 Status changed from planning to recruiting, according to a Zynerba Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top